1-209633069-C-T
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000228.3(LAMB3):c.628+1G>A variant causes a splice donor, intron change. The variant allele was found at a frequency of 0.00000312 in 1,603,308 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000228.3 splice_donor, intron
Scores
Clinical Significance
Conservation
Publications
- junctional epidermolysis bullosaInheritance: AR Classification: DEFINITIVE Submitted by: Myriad Women’s Health
- junctional epidermolysis bullosa Herlitz typeInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Orphanet, Laboratory for Molecular Medicine
- junctional epidermolysis bullosa, non-Herlitz typeInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Genomics England PanelApp, Ambry Genetics
- amelogenesis imperfecta type 1AInheritance: AD Classification: STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics
- amelogenesis imperfecta type 1Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- generalized junctional epidermolysis bullosa non-Herlitz typeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| LAMB3 | NM_000228.3 | c.628+1G>A | splice_donor_variant, intron_variant | Intron 7 of 22 | ENST00000356082.9 | NP_000219.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| LAMB3 | ENST00000356082.9 | c.628+1G>A | splice_donor_variant, intron_variant | Intron 7 of 22 | 1 | NM_000228.3 | ENSP00000348384.3 | |||
| LAMB3 | ENST00000367030.7 | c.628+1G>A | splice_donor_variant, intron_variant | Intron 7 of 22 | 1 | ENSP00000355997.3 | ||||
| LAMB3 | ENST00000391911.5 | c.628+1G>A | splice_donor_variant, intron_variant | Intron 6 of 21 | 1 | ENSP00000375778.1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152148Hom.: 0 Cov.: 33 show subpopulations
GnomAD4 exome AF: 0.00000207 AC: 3AN: 1451160Hom.: 0 Cov.: 29 AF XY: 0.00000138 AC XY: 1AN XY: 722768 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152148Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74336 show subpopulations
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Identified with a second LAMB3 variant in an individual with a clinical diagnosis of junctional epidermolysis bullosa (PMID: 7550237); Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 25525159, 7550237) -
This sequence change affects a donor splice site in intron 7 of the LAMB3 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in LAMB3 are known to be pathogenic (PMID: 11023379, 16473856). This variant is present in population databases (no rsID available, gnomAD 0.01%). Disruption of this splice site has been observed in individual(s) with epidermolysis bullosa (PMID: 7550237). ClinVar contains an entry for this variant (Variation ID: 370503). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -
Junctional epidermolysis bullosa gravis of Herlitz Pathogenic:1
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
Junctional epidermolysis bullosa Pathogenic:1
Variant summary: LAMB3 c.628+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes the canonical 5' splicing donor site. At least one publication reports experimental evidence that this variant affects mRNA splicing (example: Pulkkinen_1995). The variant was absent in 251490 control chromosomes (gnomAD). c.628+1G>A has been reported in the literature in at-least one individual affected with Junctional Epidermolysis Bullosa (example: Pulkkinen_1995). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at